Opinion|Videos|July 5, 2024
Expert Insights on Managing Amivantamab Infusion Reactions, Dosing, and Medication
A pharmacy expert explores infusion-related reactions associated with amivantamab, providing guidance on managing and preventing these reactions, while also addressing the role of split-dosing, premedications, and steroids in the treatment paradigm.
Advertisement
Episodes in this series
- Compared to the other EGFR-targeted therapies used in metastatic NSCLC, amivantamab is unique in carrying a risk for infusion-related reactions. What has been your experience with these infusion-related reactions, and what is the typical timing and severity of these reactions?
- What preventative strategies do you recommend to help prevent infusion-related reactions with amivantamab?
- Please discuss package insert recommendations including split-dosing and premedications, and if patients still experience infusion reactions despite these measures. Please discuss the role of preemptively including steroids as part of routine premedication (particularly when given as monotherapy and not already receiving steroids for pemetrexed purposes).
- In your experience and in the context of these toxicities, how do patient-specific factors such as performance status and comorbidities influence the choice of EGFR-targeted therapies?
- Please address considerations related to monotherapy vs. combination therapy (either with chemotherapy or other non-chemotherapy agents)
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Lynkuet Access Program Aims to Help Women Save on Neurokinin-Targeted Therapy
2
Fall 2025 Quiz: Test Your Pharmacy Knowledge!
3
FDA Approves Blenrep for Treatment of Relapsed or Refractory Multiple Myeloma
4
Hormone Therapy Use, Understanding, and Perceptions Have Positively Shifted From 2021 to 2025
5
